Participate in Research at CU Anschutz

To evaluate the safety, tolerability, and efficacy of TTI-101 given in combination with Stereotactic Body Radiation Therapy (SBRT) in borderline resectable pancreatic ductal adenocarcinoma.

This study plans to learn more about how safe and effective the combination of beam radiation known as Stereotactic Body Radiation Therapy (SBRT) and a drug called TTI-101 is in patients with borderline resectable pancreatic cancer. SBRT is a procedure that uses multiple beams of targeted radiation with the goal of shrinking your pancreatic tumor/s. TTI-101 is a drug that aims to slow the growth of your tumor/s. SBRT may be considered standard treatment for your cancer. However, TTI-101 is not FDA approved for any indication. Therefore, the use of SBRT and this drug in this study is considered to be investigational. You are being asked to be in this research study because you have been diagnosed with borderline resectable pancreatic cancer.